Invention Application
WO2018067331A1 BI SPECIFIC ANTI-MUC16-CD3 ANTIBODIES AND NTI-MUC16 DRUG CONJUGATES
审中-公开
BI特异性抗-MUC16-CD3抗体和NTI-MUC16药物偶联物
- Patent Title: BI SPECIFIC ANTI-MUC16-CD3 ANTIBODIES AND NTI-MUC16 DRUG CONJUGATES
- Patent Title (中): BI特异性抗-MUC16-CD3抗体和NTI-MUC16药物偶联物
-
Application No.: PCT/US2017/053113Application Date: 2017-09-22
-
Publication No.: WO2018067331A1Publication Date: 2018-04-12
- Inventor: HABER, Lauric , SMITH, Eric , KELLY, Marcus , KIRSHNER, Jessica R. , COETZEE, Sandra , CRAWFORD, Alison , NITTOLI, Thomas , LIU, Yashu
- Applicant: REGENERON PHARMACEUTICALS, INC.
- Applicant Address: 777 Old Saw Mill River Road Tarrytown, New York 10591 US
- Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee Address: 777 Old Saw Mill River Road Tarrytown, New York 10591 US
- Agency: TERMES, Lance A.
- Priority: US62/399,249 20160923; US62/558,711 20170914
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C07K16/30 ; C07K16/44 ; C07K16/46
Abstract:
The present disclosure provides anti mucin 16 antibodies : bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. human IgG antibodies that bind to human andMUC16 (monospecific antibodies).anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo The antibodies are useful for the treatment of various cancers, including ovarian cancer.
Public/Granted literature
- WO2018067331A9 BI SPECIFIC ANTI-MUC16-CD3 ANTIBODIES AND ANTI-MUC16 DRUG CONJUGATES Public/Granted day:2018-04-12
Information query
